GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Brii Biosciences Ltd (HKSE:02137) » Definitions » Other Current Assets

Brii Biosciences (HKSE:02137) Other Current Assets : HK$114.45 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Brii Biosciences Other Current Assets?

Brii Biosciences's other current assets for the quarter that ended in Dec. 2023 was HK$114.45 Mil.

Brii Biosciences's quarterly other current assets increased from Dec. 2022 (HK$75.90 Mil) to Jun. 2023 (HK$119.66 Mil) but then declined from Jun. 2023 (HK$119.66 Mil) to Dec. 2023 (HK$114.45Mil).

Brii Biosciences's annual other current assets increased from Dec. 2021 (HK$65.17 Mil) to Dec. 2022 (HK$75.90 Mil) increased from Dec. 2022 (HK$75.90 Mil) to Dec. 2023 (HK$114.45 Mil).


Brii Biosciences Other Current Assets Historical Data

The historical data trend for Brii Biosciences's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brii Biosciences Other Current Assets Chart

Brii Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Other Current Assets
5.38 44.00 65.17 75.90 114.45

Brii Biosciences Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Other Current Assets Get a 7-Day Free Trial Premium Member Only 65.17 76.99 75.90 119.66 114.45

Brii Biosciences Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.


Brii Biosciences Other Current Assets Related Terms

Thank you for viewing the detailed overview of Brii Biosciences's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Brii Biosciences (HKSE:02137) Business Description

Traded in Other Exchanges
Address
No. 1 North Yongtaizhuang Road, 3rd Floor, Building 7, Zhongguancun Dongsheng, International Science Park, Haidian District, Beijing, CHN, 100192
Brii Biosciences Ltd is a biotechnology company based in China and the United States. It is committed towards developing advancing therapies for infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as the CNS diseases, which have public health burdens in China and worldwide. The company's pipeline of products includes more than 10 product candidates that focus on infectious diseases and mental illnesses.
Executives
Hong Zhi 2101 Beneficial owner
Xyxy Holdings Ltd. 2201 Interest of corporation controlled by you
Booming Passion Limited 2101 Beneficial owner
Boyu Capital Fund Iii, L.p. 2201 Interest of corporation controlled by you
Boyu Capital General Partner Iii, L.p. 2201 Interest of corporation controlled by you
Boyu Capital General Partner Iii, Ltd 2201 Interest of corporation controlled by you
Tong Xiaomeng 2201 Interest of corporation controlled by you
Boyu Group, Llc 2201 Interest of corporation controlled by you
Boyu Capital Group Holdings Ltd 2201 Interest of corporation controlled by you
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Invesco Advisers, Inc. 2102 Investment manager
Ma Yun 2201 Interest of corporation controlled by you
Yunfeng Investment Iii, Ltd. 2201 Interest of corporation controlled by you
Yunfeng Fund Iii, L.p. 2201 Interest of corporation controlled by you
Yf Bright Insight Limited 2101 Beneficial owner

Brii Biosciences (HKSE:02137) Headlines

No Headlines